# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K232522   
B Applicant ARK Diagnostics, Inc.   
C Proprietary and Established Names ARK Levetiracetam II Assay   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>ORI</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.3350 -DiphenylhydantoinTest System</td><td rowspan=1 colspan=1>TX - ClinicalToxicology</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: New device   
B Measurand: Levetiracetam   
C Type of Test: Homogeneous enzyme immunoassay (EIA)

# III Intended Use/Indications for Use:

# A Intended Use(s):

See Indications for Use below.

# B Indication(s) for Use:

ARK Levetiracetam II Assay: The ARK Levetiracetam II Assay is a homogeneous enzyme immunoassay intended for the quantitative determination of levetiracetam in human serum or plasma on automated clinical chemistry analyzers. Levetiracetam concentrations can be used as an aid in management of patients treated with levetiracetam.

C Special Conditions for Use Statement(s): Rx - For Prescription Use Only

# D Special Instrument Requirements:

The assay has been validated on the Beckman Coulter AU680.

# IV Device/System Characteristics:

# A Device Description:

The ARK Levetiracetam II Assay consists of reagents R1 anti-levetiracetam monoclonal antibody with substrate and R2 levetiracetam labeled with bacterial G6PDH enzyme.

# B Principle of Operation:

The ARK Levetiracetam II Assay is a homogeneous immunoassay based on competition between drug in the specimen and levetiracetam labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for binding to the antibody reagent. As the latter binds antibody, enzyme activity decreases. In the presence of drug from the specimen, enzyme activity increases and is directly related to the drug concentration. Active enzyme converts the coenzyme nicotinamide adenine dinucleotide (NAD) to NADH that is measured spectrophotometrically as a rate of change in absorbance. Endogenous serum G6PDH does not interfere with the results because the coenzyme NAD functions only with the bacterial enzyme used in the assay.

# V Substantial Equivalence Information:

A Predicate Device Name(s): Ark Levetiracetam Assay   
B Predicate 510(k) Number(s): K091653

C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K232522</td><td colspan="1" rowspan="1">K091653</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">ARK Levetiracetam II</td><td colspan="1" rowspan="1">ARK Levetiracetam</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Assay</td><td colspan="1" rowspan="1">Assay</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Similarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use/IndicationsFor Use</td><td colspan="1" rowspan="1">For the quantitativedetermination oflevetiracetam in humanserum or plasma onautomated clinicalchemistry analyzers.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Specimen</td><td colspan="1" rowspan="1">Serum or plasma</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Homogeneous enzymeimmunoassay (EIA)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Platform required</td><td colspan="1" rowspan="1">Automated clinicalchemistry analyzer</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Accessary reagents</td><td colspan="1" rowspan="1">Calibrators (six levels)and controls (threelevels)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measurement range</td><td colspan="1" rowspan="1">2.0 to 100.0 μg/mL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Differences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Reagent components</td><td colspan="1" rowspan="1">Anti-levetiracetamAntibody/SubstrateReagent (R1)containing rabbitmonoclonalantibodies tolevetiracetam</td><td colspan="1" rowspan="1">Anti-levetiracetamAntibody/SubstrateReagent (R1)containing rabbitpolyclonalantibodies tolevetiracetam</td></tr></table>

# VI Standards/Guidance Documents Referenced:

CLSI Guideline EP 17-A2: Evaluation of Detection Capability for Clinical Laboratory   
Measurement Procedures   
CLSI Guideline EP5-A3: Evaluation of Precision Performance of Quantitative Measurement   
Methods   
CLSI Guideline EP6-Ed2: Evaluation of the Linearity of Quantitative Measurement Procedures:   
A Statistical Approach   
CLSI Guideline EP7-Ed3: Interference Testing in Clinical Chemistry   
CLSI Guideline EP37: Supplemental Tables for Interference Testing in Clinical Chemistry

VII Performance Characteristics (if/when applicable):

A Analytical Performance:

1. Precision/Reproducibility:

Precision studies were performed based upon recommendations in the CLSI EP05-A3 guideline. Tri-level controls and three samples of levetiracetam in three pooled human serum samples were used in the study. Data were collected on a single analyzer over twenty (20) non-consecutive days. Each level was assayed in quadruplicate twice a day. Each of the runs per day was separated by at least two hours. The within run, between day, and total imprecision estimates were calculated. Results are shown below.

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Day</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Mean(μg/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=3>ARK LevetiracetamII Control</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>30.5</td><td rowspan=1 colspan=1>0.45</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>75.7</td><td rowspan=1 colspan=1>1.41</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2.19</td><td rowspan=1 colspan=1>2.9</td></tr><tr><td rowspan=1 colspan=2>Human Serum</td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>Mid</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>32.6</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.61</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>80.5</td><td rowspan=1 colspan=1>1.62</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.80</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.79</td><td rowspan=1 colspan=1>2.2</td></tr></table>

2. Linearity:

Linearity studies were performed based upon recommendations in CLSI EP06-Ed2. Ten (10) levels of samples ranging from 2 to $1 0 0 ~ \mu \mathrm { g / m L }$ were prepared from a gravimetrically prepared levetiracetam stock solution and levetiracetam-free serum pools. The averaged results of multiple runs and replicates $( \mathrm { n } { = } 6 )$ for each sample using the ARK Levetiracetam II Assay were used in the calculations. Regression analyses were performed between the measured mean levetiracetam and the nominal values for each dilution, using weighted linear regression analysis according to CLSI/NCCLS EP6-Ed2 and results are shown below. The regression equation calculated according to EP06-Ed2 is $\mathbf { y } { = } 1 . 0 0 3 \mathbf { x }$ .

<table><tr><td colspan="1" rowspan="1">Estimated Value(μg/mL)</td><td colspan="1" rowspan="1">Results(μg/mL)</td><td colspan="1" rowspan="1">PredictedResults</td><td colspan="1" rowspan="1">%Difference</td></tr><tr><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td></tr><tr><td colspan="1" rowspan="1">2.0</td><td colspan="1" rowspan="1">1.88</td><td colspan="1" rowspan="1">2.01</td><td colspan="1" rowspan="1">11.2</td></tr><tr><td colspan="1" rowspan="1">3.0</td><td colspan="1" rowspan="1">3.2</td><td colspan="1" rowspan="1">3.04</td><td colspan="1" rowspan="1">5.9</td></tr><tr><td colspan="1" rowspan="1">4.0</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">4.07</td><td colspan="1" rowspan="1">3.3</td></tr><tr><td colspan="1" rowspan="1">6.0</td><td colspan="1" rowspan="1">6.1</td><td colspan="1" rowspan="1">6.13</td><td colspan="1" rowspan="1">0.7</td></tr><tr><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">11.0</td><td colspan="1" rowspan="1">10.25</td><td colspan="1" rowspan="1">-1.5</td></tr><tr><td colspan="1" rowspan="1">20.0</td><td colspan="1" rowspan="1">20.0</td><td colspan="1" rowspan="1">20.56</td><td colspan="1" rowspan="1">-3.5</td></tr><tr><td colspan="1" rowspan="1">40.0</td><td colspan="1" rowspan="1">42.0</td><td colspan="1" rowspan="1">41.18</td><td colspan="1" rowspan="1">-5.2</td></tr><tr><td colspan="1" rowspan="1">60.0</td><td colspan="1" rowspan="1">62.1</td><td colspan="1" rowspan="1">61.80</td><td colspan="1" rowspan="1">-6.4</td></tr><tr><td colspan="1" rowspan="1">80.0</td><td colspan="1" rowspan="1">78.9</td><td colspan="1" rowspan="1">82.42</td><td colspan="1" rowspan="1">-7.5</td></tr><tr><td colspan="1" rowspan="1">100.0</td><td colspan="1" rowspan="1">105.4</td><td colspan="1" rowspan="1">103.03</td><td colspan="1" rowspan="1">-8.6</td></tr></table>

Analytical recovery:

Serum samples across the assay range were prepared containing levetiracetam (sourced from USP). The results of the six replicates were averaged and compared to the theoretical target concentration and the percentage recovery was calculated. Results are shown below.

(Percent Recovery = 100 x Mean recovered concentration/Theoretical concentration)   

<table><tr><td rowspan=1 colspan=1>TheoreticalConcentration(μg/mL)</td><td rowspan=1 colspan=1>Mean RecoveredConcentration (μg/mL)</td><td rowspan=1 colspan=1>PercentRecovery</td></tr><tr><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>95.0</td></tr><tr><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>97.5</td></tr><tr><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>9.8</td><td rowspan=1 colspan=1>98.0</td></tr><tr><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>20.1</td><td rowspan=1 colspan=1>100.5</td></tr><tr><td rowspan=1 colspan=1>45.0</td><td rowspan=1 colspan=1>46.2</td><td rowspan=1 colspan=1>102.6</td></tr><tr><td rowspan=1 colspan=1>80.0</td><td rowspan=1 colspan=1>77.8</td><td rowspan=1 colspan=1>97.3</td></tr><tr><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.3</td><td rowspan=1 colspan=1>100.3</td></tr></table>

A manual dilution protocol has not been validated to enable measurements of concentrations above the measurement range.

# 3. Analytical Specificity/Interference:

Interference studies were carried out based upon recommendations in CLSI EP7-A3.

Interference was tested using serum pools at two levels of levetiracetam, 15 and $5 0 ~ \mu \mathrm { g / m L }$ . Each sample was assayed using the ARK Levetiracetam II Assay, along with a serum control of levetiracetam. Bias exceeding $10 \%$ is considered significant interference. The highest concentration of interferent tested that did not cause significant interference is summarized in the table below.

<table><tr><td colspan="4" rowspan="1">Percentage Recovery</td></tr><tr><td colspan="1" rowspan="1">Interfering Substance</td><td colspan="1" rowspan="1">InterferentConcentration</td><td colspan="1" rowspan="1">15 μg/mLLevetiracetam</td><td colspan="1" rowspan="1">50 μg/mLLevetiracetam</td></tr><tr><td colspan="1" rowspan="1">Human Albumin</td><td colspan="1" rowspan="1">12 g/dL</td><td colspan="1" rowspan="1">98.7</td><td colspan="1" rowspan="1">99.9</td></tr><tr><td colspan="1" rowspan="1">Bilirubin - conjugated</td><td colspan="1" rowspan="1">72 mg/dL</td><td colspan="1" rowspan="1">100.2</td><td colspan="1" rowspan="1">100.9</td></tr><tr><td colspan="1" rowspan="1">Bilirubin - unconjugated</td><td colspan="1" rowspan="1">72 mg/dL</td><td colspan="1" rowspan="1">101.7</td><td colspan="1" rowspan="1">97.1</td></tr><tr><td colspan="1" rowspan="1">Cholesterol</td><td colspan="1" rowspan="1">620 mg/dL</td><td colspan="1" rowspan="1">94.9</td><td colspan="1" rowspan="1">100.8</td></tr><tr><td colspan="1" rowspan="1">Human Gamma-Globulin</td><td colspan="1" rowspan="1">12 g/dL</td><td colspan="1" rowspan="1">102.7</td><td colspan="1" rowspan="1">98.7</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">1050 mg/dL</td><td colspan="1" rowspan="1">100.9</td><td colspan="1" rowspan="1">95.8</td></tr><tr><td colspan="1" rowspan="1">Intralipid</td><td colspan="1" rowspan="1">2000 mg/dL</td><td colspan="1" rowspan="1">98.7</td><td colspan="1" rowspan="1">100.4</td></tr><tr><td colspan="1" rowspan="1">Rheumatoid Factor</td><td colspan="1" rowspan="1">1080 IU/mL</td><td colspan="1" rowspan="1">98.8</td><td colspan="1" rowspan="1">94.5</td></tr><tr><td colspan="1" rowspan="1">Triglycerides</td><td colspan="1" rowspan="1">1670 mg/dL</td><td colspan="1" rowspan="1">98.6</td><td colspan="1" rowspan="1">95.9</td></tr><tr><td colspan="1" rowspan="1">Uric Acid</td><td colspan="1" rowspan="1">30 mg/dL</td><td colspan="1" rowspan="1">91.0</td><td colspan="1" rowspan="1">98.8</td></tr></table>

Specificity: Metabolite 2-pyrrolidone-N-butyric acid (ucb L057) was also tested for cross-reactivity.   

<table><tr><td rowspan=2 colspan=1>Metabolite</td><td rowspan=2 colspan=1>Concentration(μg/mL)</td><td rowspan=1 colspan=2>Percent Recovery</td></tr><tr><td rowspan=1 colspan=1>Levetiracetam15 μg/mL</td><td rowspan=1 colspan=1>Levetiracetam50 μg/mL</td></tr><tr><td rowspan=1 colspan=1>2-pyrrolidone-N-butyric acid</td><td rowspan=1 colspan=1>250.0</td><td rowspan=1 colspan=1>101.4</td><td rowspan=1 colspan=1>100.2</td></tr></table>

Drug interference:

Brivaracetam (Briviact) interferes with measurements of levetiracetam (Keppra) in the ARK Levetiracetam II Assay. Patients undergoing a switch in drug therapy involving Keppra and Briviact should not be monitored for levetiracetam using the ARK assay if there is a possibility these drugs are co-present in circulation.

The device was not impacted by other structurally unrelated drugs tested. A high concentration of each compound was spiked into normal human serum with known levels of levetiracetam (approximately 15 and $5 0 ~ \mu \mathrm { g / m L }$ ) and assayed along with a serum control of levetiracetam. Measurement of levetiracetam resulted in $\leq 1 0 \%$ error in the presence of drug compounds at the levels tested.

<table><tr><td colspan="1" rowspan="1">Compound</td><td colspan="1" rowspan="1">Concentration(μg/mL)</td><td colspan="1" rowspan="1">Compound</td><td colspan="1" rowspan="1">Concentration(μg/mL)</td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">Nortriptyline</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic acid</td><td colspan="1" rowspan="1">1000</td><td colspan="1" rowspan="1">Oxcarbazepine</td><td colspan="1" rowspan="1">50</td></tr><tr><td colspan="1" rowspan="1">Amitriptyline</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">Phenobarbital</td><td colspan="1" rowspan="1">200</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">Phenytoin</td><td colspan="1" rowspan="1">200</td></tr><tr><td colspan="1" rowspan="1">Carbamazepine</td><td colspan="1" rowspan="1">120</td><td colspan="1" rowspan="1">Primidone</td><td colspan="1" rowspan="1">100</td></tr><tr><td colspan="1" rowspan="1">Clonazepam</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">Probenecid</td><td colspan="1" rowspan="1">600</td></tr><tr><td colspan="1" rowspan="1">Cyclosporin A</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">Salicylic Acid</td><td colspan="1" rowspan="1">500</td></tr><tr><td colspan="1" rowspan="1">Diazepam</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">Sulfamethoxazole</td><td colspan="1" rowspan="1">400</td></tr><tr><td colspan="1" rowspan="1">Digoxin</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">Sulfisoxazole</td><td colspan="1" rowspan="1">400</td></tr><tr><td colspan="1" rowspan="1">Erythromycin</td><td colspan="1" rowspan="1">200</td><td colspan="1" rowspan="1">Theophylline</td><td colspan="1" rowspan="1">250</td></tr><tr><td colspan="1" rowspan="1">Ethosuximide</td><td colspan="1" rowspan="1">250</td><td colspan="1" rowspan="1">Tiagabine</td><td colspan="1" rowspan="1">200</td></tr><tr><td colspan="1" rowspan="1">Felbamate</td><td colspan="1" rowspan="1">250</td><td colspan="1" rowspan="1">Topiramate</td><td colspan="1" rowspan="1">250</td></tr><tr><td colspan="1" rowspan="1">Gabapentin</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">Trimethoprim</td><td colspan="1" rowspan="1">40</td></tr><tr><td colspan="1" rowspan="1">Heparin</td><td colspan="1" rowspan="1">200 units/mL</td><td colspan="1" rowspan="1">Valproic Acid</td><td colspan="1" rowspan="1">500</td></tr><tr><td colspan="1" rowspan="1">Hydrochlorothiazide</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">Verapamil</td><td colspan="1" rowspan="1">100</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">Vigabatrin</td><td colspan="1" rowspan="1">150</td></tr><tr><td colspan="1" rowspan="1">Lamotrigine</td><td colspan="1" rowspan="1">250</td><td colspan="1" rowspan="1">Warfarin</td><td colspan="1" rowspan="1">250</td></tr><tr><td colspan="1" rowspan="1">Naproxen</td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">Zonisamide</td><td colspan="1" rowspan="1">250</td></tr></table>

4. Assay Reportable Range: The manufacturer’s claimed assay reportable range is from 2.0 to $1 0 0 ~ \mu \mathrm { g / m L }$ .

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods): The device is traceable to commercially available reference materials.

6. Detection Limit:

The LOQ of the ARK Levetiracetam II Assay was determined using three reagent lots and the results supported an LOQ of $2 . 0 ~ \mu \mathrm { g / m L }$ with the manufacturer’s acceptance criteria of CV within $20 \%$ and recovery within $+ / - 1 5 \%$ .

7. Assay Cut-Off:

Not applicable.

# B Comparison Studies:

# 1. Method Comparison with Predicate Device:

Method comparison studies were performed to evaluate the performance of the ARK Levetiracetam II Assay. 104 serum patient samples spanning the range of $3 . 4 ~ \mu \mathrm { g / m L }$ to 98.3 $\mu \mathrm { g / m L }$ were tested on one assay lot with each sample tested in singlicate. Measurements obtained with the ARK Levetiracetam II Assay were made on the Beckman Coulter AU680 analyzer, while measurements of levetiracetam by the predicate assay were made on the Roche Hitachi 917 analyzer. Results from the candidate device were compared to the predicate device and results of the Passing- Bablok regression analysis for the study are shown below.

$$
\mathrm { Y } = 1 . 0 4 \mathrm { X } - 0 . 3 0 , \mathrm { R } ^ { 2 } = 0 . 9 9
$$

# 2. Matrix Comparison:

The sponsor provided studies that were adequate to support the use of the following anticoagulants: lithium heparin, sodium heparin, and potassium EDTA with the ARK II Levetiracetam II Assay.

# C Clinical Studies:

1. Clinical Sensitivity:

Not applicable.

2. Clinical Specificity: Not applicable.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):

# D Clinical Cut-Off:

See expected values.

# E Expected Values/Reference Range:

The following statement is included in the package insert:

A reference range for levetiracetam has not been well established. Reference ranges for seizure control have been proposed, which include serum/plasma trough concentrations from 6 to 46 $\mu \mathrm { g / m L }$ (35 to $2 7 0 \mu \mathrm { m o l / L } )$ or 10 to $4 0 ~ \mu \mathrm { g / m L }$ (59 to $2 3 5 \mu \mathrm { m o l / L } $ ) including a laboratory alert level at $5 0 ~ \mu \mathrm { g / m L }$ $( 2 9 4 \mu \mathrm { m o l / L } )$ ). However, these ranges have not been validated by adequate controlled trials, and in general the relationship between these serum concentrations and clinical effect has not been well-defined. Levetiracetam drug concentrations should be used in conjunction with information available from clinical evaluations and other diagnostic procedures. Circulating levels of levetiracetam (serum blood concentrations) may be affected by compliance, renal function, pregnancy, drug-drug interactions and timing of the sample draw. Furthermore, the clinical effect of these serum blood concentrations may be further altered by changes in progression in the severity of the disease and the addition or withdrawal of concomitant drugs which may interact pharmacodynamically with circulating levels of levetiracetam.

The reference range of drug concentrations which is quoted should only imply a lower limit below which a therapeutic response is relatively unlikely to occur, and an upper limit above which toxicity is relatively likely to occur in the specific patient populations studied. Generally, clinicians using reference ranges such as these should be aware that, because of individual variation, patients may achieve therapeutic benefit with serum drug concentrations outside of these ranges and may experience toxicity with levels below the lower limit of the reference range. Sampling time should be standardized such that trough serum concentrations are measured just before the next dosage, preferably in the morning.

# VIII Proposed Labeling:

The labeling support the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.